Thursday, August 9, 2012
A team at the Memorial Sloan-Kettering Cancer Center has shown that CXC chemokine receptor 2 antagonists sensitized tumors to chemotherapy in mouse
models of metastatic breast cancer.1 The team is working on
additional preclinical studies with the intention of moving the antagonists
into clinical trials for breast cancer.
Before CXCR2 antagonists can be tested
in combination with chemotherapeutics in the clinic, researchers agree that
extensive preclinical evaluation of efficacy will be required. It will also be
necessary to address a few potential adverse effects.
In addition to the potential therapeutic
applications of the findings, the team thinks the results have important
implications for breast cancer diagnosis and prognosis.
Martz, L. SciBX 5(31);
Published online Aug. 9, 2012
1. Acharyya, S. et al. Cell; published online July 6, 2012;
Contact: Joan Massagué, Memorial Sloan-Kettering Cancer
Center, New York, N.Y.
2. Minn, A.J. et al. Nature 436, 518-524 (2005)
AND INSTITUTIONS MENTIONED
AstraZeneca plc (LSE:AZN; NYSE:AZN), London U.K.
Cancer Research UK, London, U.K.
Dompe Farmaceutici S.p.A., Milan, Italy
Howard Hughes Medical Institute, Chevy Chase, Md.
Memorial Sloan-Kettering Cancer Center, New York, N.Y.
The University of Tokyo Hospital, Tokyo, Japan